title: Pharmacokinetics of oral rosiglitazone in Taiwanese and post hoc comparisons with Caucasian, Japanese, Korean, and mainland Chinese subjects.
abstract: OBJECTIVE
  Rosiglitazone, an insulin-sensitizing thiazolidinedione, acts as a ligand for the y-subtype of the peroxisome proliferator-activated receptor in the regulation of glucose homeostasis and lipid metabolism. The aims of this study were to determine the pharmacokinetics of oral rosiglitazone in Taiwanese and to post hoc compare the ethnic differences among Caucasian, Japanese, Korean, and Mainland Chinese.
  
  
  METHODS
  Twelve Taiwanese healthy male subjects received 4 and 8 mg of rosiglitazone. Similar protocols were used in the previously unpublished studies conducted in 25 Caucasian, 32 Japanese, 8 Korean, and 12 Mainland Chinese healthy male subjects. The 4 mg dose data were used for ethnicity comparisons.
  
  
  RESULTS
  The respective pharmacokinetic properties of Taiwanese, Caucasian, Japanese, Korean and Mainland Chinese are: terminal half-life (hr): 4.18 +/- 0.43, 3.96 +/- 1.31, 3.83 +/- 0.78, 4.70 +/- 1.19 and 4.37 +/- 0.63; Cmax (ng/ml): 384.1 +/- 59.3, 260.2 +/- 75.7, 401.9 +/- 102.3, 345.3 +/- 60.6, and 406.2 +/- 52.0; AUC0-inf (h*ng/ml): 2078 +/- 433, 1249 +/- 566, 1901 +/- 397, 1938 +/- 534, and 2158 +/- 498. The Cmax and AUC0-inf of Caucasian were significantly (p = 0.002, 0.008) lower and CL/F and V/F were significantly (p = 0.000, 0.003) higher than those of other races. These differences of Cmax, AUC0-inf, CL/F and V/F between Caucasian and other races became insignificant after normalized by dose and weight.
  
  
  CONCLUSIONS
  In a given dose by body weight, ethnicity had no significant impact on the pharmacokinetics of rosiglitazone in normal healthy volunteers.
authors.affiliation: Division of Cardiology, Tri-Service General Hospital, National Defense Medical Center.
authors.forename: Kai-Min
authors.initials: KM
authors.lastname: Chu
authors.forename: Oliver Yoa-Pu
authors.initials: OY
authors.lastname: Hu
authors.forename: Li-Heng
authors.initials: LH
authors.lastname: Pao
authors.forename: Cheng-Huei
authors.initials: CH
authors.lastname: Hsiong
mesh_terms: D000284:Administration, Oral; D000328:Adult; D044466:Asian People / Q000235:genetics*; D018592:Cross-Over Studies; D006207:Half-Life; D006801:Humans; D007723:Korea; D008297:Male; D008875:Middle Aged; D000077154:Rosiglitazone; D013624:Taiwan; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D045162:Thiazolidinediones; D000077154:Rosiglitazone